Abstract: Cat food includes: food granules including extruded puffed granules having a moisture content of 12% or less. 60% or more of the food granules have a hardness of 2.5 kgw or less 1 minute after being immersed in a dilute hydrochloric acid (pH of 2.5) at 25° C. for 10 minutes. A pepsin digestibility of the food granules, 1 minute after being immersed in a 500 U/mL pepsin hydrochloric acid solution at 38° C. for 4 hours, is 60% or more.

Abstract: A composition comprises: a base oil; an additive comprising a copolymer comprising hydrophobic and hydrophilic units; and a drug. The copolymer may for example have a comb structure in which the hydrophobic units and hydrophilic units are pendant chains on a backbone of the copolymer. The hydrophobic units and hydrophilic units may for example comprise polydimethylsiloxane moieties and ethylene glycol residues respectively. The composition may for example be used as a tamponade or as a component for a tamponade administered to the eye. The invention is useful for solubilising and/or releasing drugs.

Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Abstract: In one aspect, the disclosure relates to methods and compositions, i.e., pharmaceutical formulations, for treating and preventing diabetic foot ulcers. In a particular aspect, the disclosed methods and compositions pertain to water-based pharmaceutical formulations that are useful for administration in an aqueous foot bath. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono ?-lactone, wherein the glucono ?-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono ?-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Provided is a composition for the treatment of keratin fibers, for example human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition ranges from 1.5 to 4.5. Also provided is a composition for the treatment of keratin fibers, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition is alkaline. Also provided is a method for treating keratin fibers, comprising applying, to the keratin fibers, at least one oxidizing composition described herein.

Abstract: An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.

Abstract: Exemplary compositions, methods, systems, and kits are disclosed that render excess pharmaceuticals safe by chemically transforming the active pharmaceutical ingredient into an environmentally benign and biologically inert form. The methods and kits have additional advantages of convenience, low cost, long shelf life, and ease of handling.

Abstract: The present invention is directed to a personal care composition comprising from about 10% to about 25% of one or more surfactants; from about 0.1% to 10% of sulfur; wherein the sulfur has a mean particle size (D50) of from about 5 ?m to about 150 ?m; from about 0.05% to about 10% of one or more stabilizing polymers; and from about 0.01% to about 4% of a suspending wax.

Abstract: There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

Abstract: The present invention relates to HPMA-CBz copolymers and methods for treating certain diseases comprising administering the copolymers to a subject in need thereof.

Abstract: A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.

Abstract: Provided is a polyurethane gel composition containing A and B below. Here, A represents a polyurethane obtained by reaction of (a) a hydrogenated polybutadiene having isocyanate groups at the terminals and (b) a glycol represented by HO—R3—OH (wherein R3 represents a linear or branched C2 to C6 alkylene group optionally having an ether bond), or A represents a polyurethane obtained by reaction of (c) a hydrogenated polybutadiene having hydroxyl groups at the terminals, (d) a diisocyanate compound, and the (b) glycol represented by HO—R3—OH (wherein R3 represents a linear or branched C2 to C6 alkylene group optionally having an ether bond), and B represents an oil agent. The polyurethane gel composition of the present invention is particularly useful as a raw material for cosmetics since a film of an oil-soluble gel obtained using the polyurethane gel composition is exceptionally excellent in any point of transparency, high gloss, elasticity, and resilience.

Abstract: A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.

Abstract: The present disclosure relates to benzene-1,3,5-tricarboxamide derived ester lipid compounds, compositions, lipid-like nanoparticles, and methods for delivery of therapeutic, diagnostic, or prophylactic agents.

Abstract: A pharmaceutically acceptable composition comprising trehalose and a pharmaceutically acceptable excipient and methods of delivering autophagy stimulating trehalose to a patient in need thereof.

Abstract: Compositions and methods for protecting bees from toxins and for preventing or decreasing colony collapse are provided. The compositions comprise carbon microparticles which, when ingested by bees, increase their survival after exposure to toxins such as pesticides.

Abstract: An activated cannabinoid controlled release compound tablet and method of forming the same. In one embodiment, the tablet includes a cannabinoid and a hosting compound mixed with the cannabinoid to form a cannabinoid controlled release compound. The tablet may also include a surfactant mixed with the cannabinoid controlled release compound to form an activated cannabinoid controlled release compound.

Abstract: A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.